Constitutive	O
Neutrophil	O
Apoptosis	O
:	O
Regulation	O
by	O
Cell	O
Concentration	O
via	O
S100	B-GP
A8	I-GP
/	O
9	O
and	O
the	O
MEK	B-GP
–	O
ERK	B-GP
Pathway	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MA	O
DM	O
.	O

Performed	O
the	O
experiments	O
:	O
MA	O
AK	O
UT	O
SB	O
AG	O
IV	O
DM	O
.	O

Analyzed	O
the	O
data	O
:	O
MA	O
AK	O
UT	O
SB	O
AG	O
IV	O
DM	O
.	O

Wrote	O
the	O
paper	O
:	O
MA	O
DM	O
.	O

Programmed	O
cell	O
death	O
(	O
PCD	O
)	O
is	O
a	O
fundamental	O
mechanism	O
in	O
tissue	O
and	O
cell	O
homeostasis	O
.	O

It	O
was	O
long	O
suggested	O
that	O
apoptosis	O
regulates	O
the	O
cell	O
number	O
in	O
diverse	O
cell	O
populations	O
;	O
however	O
no	O
clear	O
mechanism	O
was	O
shown	O
.	O

Neutrophils	O
are	O
the	O
short	O
-	O
lived	O
,	O
first	O
-	O
line	O
defense	O
of	O
innate	O
immunity	O
,	O
with	O
an	O
estimated	O
t	O
=	O
1	O
/	O
2	O
of	O
8	O
hours	O
and	O
a	O
high	O
turnover	O
rate	O
.	O

Here	O
we	O
first	O
show	O
that	O
spontaneous	O
neutrophil	O
constitutive	O
PCD	O
is	O
regulated	O
by	O
cell	O
concentrations	O
.	O

Using	O
a	O
proteomic	O
approach	O
,	O
we	O
identified	O
the	O
S100	B-GP
A8	I-GP
/	O
9	O
complex	O
,	O
which	O
constitutes	O
roughly	O
40	O
%	O
of	O
cytosolic	O
protein	O
in	O
neutrophils	O
,	O
as	O
mediating	O
this	O
effect	O
.	O

We	O
further	O
demonstrate	O
that	O
it	O
regulates	O
cell	O
survival	O
via	O
a	O
signaling	O
mechanism	O
involving	O
MEK	B-GP
-	O
ERK	B-GP
via	O
TLR4	B-GP
and	O
CD11B	B-GP
/	O
CD18	B-GP
.	O

This	O
mechanism	O
is	O
suggested	O
to	O
have	O
a	O
fine	O
-	O
tuning	O
role	O
in	O
regulating	O
the	O
neutrophil	O
number	O
in	O
bone	O
marrow	O
,	O
peripheral	O
blood	O
,	O
and	O
inflammatory	O
sites	O
.	O

Introduction	O

Programmed	O
cell	O
death	O
(	O
PCD	O
)	O
is	O
a	O
fundamental	O
mechanism	O
in	O
tissue	O
and	O
cell	O
homeostasis	O
,	O
long	O
thought	O
to	O
regulate	O
cell	O
number	O
in	O
diverse	O
populations	O
.	O

In	O
developmental	O
biology	O
,	O
PCD	O
provides	O
an	O
efficient	O
mechanism	O
for	O
eliminating	O
unwanted	O
cells	O
,	O
as	O
shown	O
in	O
studies	O
with	O
the	O
nematode	B-OG
Caenorhabditis	B-OG
elegans	I-OG
[	O
1	O
].	O

Of	O
the	O
1090	O
somatic	O
cells	O
formed	O
during	O
the	O
development	O
of	O
an	O
adult	O
hermaphrodite	B-OG
,	O
exactly	O
131	O
die	O
,	O
demonstrating	O
the	O
morphological	O
features	O
of	O
apoptosis	O
.	O

In	O
the	O
mammalian	O
immune	O
system	O
,	O
clonal	O
triggering	O
results	O
in	O
lymphocyte	O
proliferation	O
followed	O
by	O
activation	O
-	O
induced	O
cell	O
death	O
that	O
ensures	O
T	O
cells	O
will	O
return	O
to	O
their	O
original	O
concentration	O
,	O
adding	O
only	O
a	O
negligible	O
number	O
of	O
memory	O
cells	O
[	O
2	O
].	O

Few	O
studies	O
in	O
the	O
human	B-OG
immune	O
system	O
have	O
questioned	O
the	O
mechanism	O
of	O
constitutive	O
leukocyte	O
blood	O
concentration	O
regulation	O
via	O
PCD	O
.	O

In	O
humans	B-OG
,	O
neutrophils	O
are	O
the	O
short	O
-	O
lived	O
,	O
first	O
-	O
line	O
defense	O
of	O
innate	O
immunity	O
,	O
with	O
estimated	O
t	O
=	O
1	O
/	O
2	O
of	O
8	O
hours	O
and	O
a	O
high	O
turnover	O
rate	O
[	O
3	O
].	O

These	O
cells	O
,	O
which	O
represent	O
50	O
–	O
60	O
%	O
of	O
the	O
circulating	O
leukocytes	O
in	O
normal	O
conditions	O
,	O
are	O
considered	O
terminally	O
differentiated	O
cells	O
.	O

They	O
are	O
rapidly	O
recruited	O
and	O
accumulate	O
in	O
the	O
early	O
phase	O
of	O
inflammation	O
.	O

Under	O
normal	O
physiological	O
conditions	O
,	O
absent	O
triggers	O
initiating	O
neutrophil	O
exit	O
from	O
the	O
blood	O
pool	O
into	O
tissues	O
,	O
human	B-OG
blood	O
neutrophil	O
counts	O
are	O
determined	O
by	O
the	O
balance	O
between	O
neutrophil	O
hematopoiesis	O
,	O
neutrophil	O
mobilization	O
from	O
the	O
bone	O
marrow	O
,	O
the	O
marginal	O
pool	O
,	O
spontaneous	O
constitutive	O
PCD	O
,	O
and	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
.	O

Human	B-OG
neutrophils	O
are	O
generated	O
in	O
bone	O
marrow	O
,	O
mainly	O
under	O
the	O
control	O
of	O
G	B-GP
-	I-GP
CSF	I-GP
and	O
additional	O
cytokines	B-GP
and	O
growth	O
factors	O
,	O
including	O
M	B-GP
-	I-GP
CSF	I-GP
,	O
GM	B-GP
-	I-GP
CSF	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
3	I-GP
(	O
reviewed	O
by	O
Metcalf	O
[	O
4	O
]),	O
and	O
possibly	O
IL	B-GP
-	I-GP
17	I-GP
and	O
IL	B-GP
-	I-GP
23	I-GP
[	O
5	O
],	O
as	O
well	O
as	O
IL	B-GP
-	I-GP
22	I-GP
.	O

Martin	O
et	O
al	O
.,	O
and	O
others	O
,	O
suggested	O
that	O
neutrophils	O
are	O
retained	O
in	O
the	O
bone	O
marrow	O
through	O
interaction	O
of	O
CXCL12	B-GP
(	O
stromal	B-GP
derived	I-GP
factor	I-GP
1	I-GP
,	O
or	O
SDF	B-GP
-	I-GP
1	I-GP
)	O
with	O
its	O
receptor	O
CXCR4	B-GP
[	O
6	O
]–[	O
7	O
].	O

In	O
the	O
blood	O
pool	O
,	O
neutrophils	O
circulate	O
until	O
they	O
are	O
marginated	O
or	O
develop	O
morphological	O
changes	O
due	O
to	O
PCD	O
,	O
and	O
are	O
cleared	O
by	O
Kupfer	O
cells	O
in	O
the	O
liver	O
[	O
8	O
]	O
or	O
by	O
bone	O
marrow	O
macrophages	O
[	O
9	O
].	O

Various	O
cytokines	B-GP
regulate	O
blood	O
neutrophil	O
counts	O
.	O

Catecholamines	O
mobilize	O
the	O
marginal	O
pool	O
[	O
10	O
],	O
while	O
G	B-GP
-	I-GP
CSF	I-GP
,	O
IL	B-GP
-	I-GP
17	I-GP
,	O
and	O
IL	B-GP
-	I-GP
23	I-GP
[	O
5	O
]	O
may	O
modify	O
counts	O
via	O
bone	O
marrow	O
.	O

Yet	O
,	O
the	O
major	O
regulator	O
of	O
blood	O
neutrophil	O
counts	O
and	O
neutrophils	O
at	O
inflammatory	O
sites	O
is	O
PCD	O
,	O
which	O
allows	O
only	O
a	O
short	O
neutrophil	O
life	O
span	O
,	O
modulated	O
according	O
to	O
specific	O
needs	O
,	O
such	O
as	O
inflammation	O
.	O

Molecular	O
events	O
leading	O
to	O
this	O
short	O
neutrophil	O
lifespan	O
are	O
better	O
understood	O
now	O
.	O

An	O
important	O
regulator	O
of	O
neutrophil	O
apoptosis	O
seems	O
to	O
be	O
the	O
Bcl	B-GP
-	I-GP
2	I-GP
protein	O
family	O
,	O
and	O
a	O
major	O
event	O
in	O
spontaneous	O
neutrophil	O
PCD	O
appears	O
related	O
to	O
loss	O
of	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

Bcl	B-GP
-	I-GP
2	I-GP
is	O
lost	O
during	O
neutrophil	O
differentiation	O
,	O
and	O
not	O
expressed	O
by	O
peripheral	O
blood	O
neutrophils	O
[	O
11	O
]–[	O
14	O
].	O

Bcl	B-GP
-	I-GP
xl	I-GP
is	O
also	O
expressed	O
by	O
neutrophils	O
,	O
and	O
expression	O
decreases	O
upon	O
TNFα	B-GP
-	O
mediated	O
apoptosis	O
[	O
14	O
].	O

Mcl1	B-GP
declines	O
as	O
neutrophils	O
undergo	O
spontaneous	O
apoptosis	O
,	O
and	O
is	O
upregulated	O
when	O
cells	O
are	O
exposed	O
to	O
survival	O
factors	O
such	O
as	O
GMCSF	B-GP
,	O
butyrate	O
,	O
ILβ	B-GP
,	O
and	O
LPS	O
[	O
12	O
].	O

A1	B-GP
,	O
expressed	O
in	O
neutrophils	O
at	O
the	O
mRNA	O
level	O
[	O
13	O
],	O
[	O
15	O
],	O
is	O
also	O
upregulated	O
by	O
survival	O
factors	O
GCSF	B-GP
and	O
LPS	O
[	O
15	O
].	O

Furthermore	O
,	O
neutrophils	O
do	O
not	O
express	O
survivin	B-GP
,	O
an	O
inhibitor	B-GP
-	I-GP
of	I-GP
-	I-GP
apoptosis	I-GP
protein	I-GP
(	O
IAP	B-GP
),	O
unless	O
expression	O
is	O
induced	O
by	O
GCSF	B-GP
and	O
GMCSF	B-GP
or	O
in	O
inflammatory	O
conditions	O
[	O
16	O
].	O

In	O
contrast	O
,	O
pro	O
-	O
apoptotic	O
proteins	O
Bax	B-GP
,	O
Bak	B-GP
,	O
and	O
Bad	B-GP
are	O
constitutively	O
expressed	O
[	O
13	O
],	O
[	O
14	O
],	O
[	O
17	O
].	O

The	O
extrinsic	O
pathway	O
may	O
also	O
be	O
involved	O
.	O

Neutrophils	O
constitutively	O
express	O
Fas	B-GP
and	O
Fas	B-GP
ligand	I-GP
,	O
although	O
the	O
importance	O
of	O
Fas	B-GP
-	O
induced	O
death	O
remains	O
controversial	O
[	O
11	O
],	O
[	O
18	O
]–[	O
20	O
].	O

In	O
addition	O
,	O
neutrophil	O
life	O
expectancy	O
can	O
be	O
modulated	O
by	O
various	O
mediators	O
(	O
G	B-GP
-	I-GP
CSF	I-GP
,	O
GM	B-GP
-	I-GP
CSF	I-GP
,	O
IL1β	B-GP
,	O
IFN	B-GP
-	I-GP
gamma	I-GP
,	O
and	O
LPS	O
[	O
21	O
]–[	O
25	O
])	O
or	O
functional	O
events	O
such	O
as	O
transmigration	O
across	O
the	O
endothelium	O
[	O
26	O
].	O

Despite	O
our	O
growing	O
understanding	O
of	O
molecular	O
control	O
of	O
neutrophil	O
PCD	O
,	O
it	O
remains	O
unclear	O
how	O
specific	O
neutrophil	O
blood	O
concentration	O
is	O
maintained	O
.	O

We	O
hypothesized	O
that	O
cell	O
concentration	O
might	O
serve	O
as	O
a	O
neutrophil	O
count	O
regulator	O
via	O
a	O
feedback	O
mechanism	O
affecting	O
PCD	O
.	O

We	O
examined	O
the	O
in	O
vitro	O
effect	O
of	O
cell	O
number	O
on	O
spontaneous	O
neutrophil	O
PCD	O
,	O
and	O
demonstrated	O
that	O
neutrophil	O
PCD	O
is	O
strongly	O
influenced	O
by	O
cell	O
concentration	O
.	O

We	O
hypothesized	O
that	O
secreted	O
molecules	O
mediate	O
this	O
effect	O
,	O
and	O
used	O
a	O
proteomic	O
approach	O
,	O
which	O
showed	O
that	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
is	O
regulated	O
by	O
cell	O
concentration	O
through	O
molecules	O
released	O
during	O
neutrophil	O
PCD	O
.	O

We	O
further	O
show	O
that	O
the	O
S100	B-GP
A8	I-GP
/	O
9	O
complex	O
is	O
a	O
primary	O
regulatory	O
molecule	O
regulating	O
cell	O
survival	O
via	O
CD11b	B-GP
/	O
CD18	B-GP
and	O
TLR4	B-GP
,	O
and	O
through	O
a	O
signaling	O
mechanism	O
involving	O
MEK	B-GP
-	O
ERK	B-GP
.	O

Materials	O
and	O
Methods	O

Materials	O

Cell	O
culture	O
medium	O
consisted	O
of	O
RPMI	O
1640	O
(	O
Invitrogen	O
-	O
Gibco	O
,	O
NY	O
)	O
supplemented	O
with	O
1	O
%	O
L	O
-	O
glutamine	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
(	O
Biological	O
Industries	O
,	O
Kibbutz	O
Beit	O
-	O
Haemek	O
,	O
Israel	O
).	O

The	O
APOPTEST	O
-	O
FITC	O
Kit	O
containing	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
was	O
obtained	O
from	O
Nexins	O
Research	O
B	O
.	O
V	O
.	O

(	O
Hoeven	O
,	O
The	O
Netherlands	O
)	O
or	O
from	O
MBL	O
International	O
(	O
Cambridge	O
,	O
MA	O
).	O

Propidium	O
iodide	O
(	O
PI	O
)	O
was	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
).	O

Recombinant	O
proteins	O
S100A8	B-GP
and	O
S100A9	B-GP
,	O
and	O
blocking	O
antibodies	B-GP
were	O
generously	O
supplied	O
by	O
Dr	O
.	O
Philippe	O
A	O
.	O

Tessier	O
.	O
(	O
Laval	O
University	O
,	O
Quebec	O
,	O
Canada	O
).	O

The	O
pan	O
-	O
caspase	B-GP
inhibitor	O
zVAD	O
-	O
fmk	O
was	O
purchased	O
from	O
R	O
&	O
D	O
systems	O
(	O
Minneapolis	O
,	O
MN	O
).	O

Mouse	B-OG
anti	O
-	O
human	B-OG
CD36	B-GP
-	O
PE	B-GP
,	O
mouse	B-OG
anti	O
-	O
human	B-OG
CD11b	B-GP
-	O
PE	B-GP
,	O
and	O
isotype	O
control	O
IgG1	B-GP
-	O
PE	B-GP
were	O
obtained	O
from	O
Serotec	O
(	O
Oxford	O
,	O
UK	O
),	O
and	O
isotype	O
control	O
mouse	B-OG
IgM	B-GP
-	O
PE	B-GP
from	O
Dako	O
(	O
Glostrup	O
,	O
Denmark	O
).	O

DiOC6	O
(	O
3	O
)	O
(	O
3	O
,	O
3	O
-	O
dihexyloxacarbocyanine	O
iodide	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
).	O

MEK	B-GP
inhibitor	O
PD98059	O
was	O
purchased	O
from	O
Cell	O
Signaling	O
(	O
Danvers	O
,	O
MA	O
).	O

Antibody	B-GP
against	O
the	O
complex	O
S100A8	B-GP
/	O
9	O
for	O
flow	O
cytometry	O
analysis	O
was	O
purchased	O
from	O
Abcam	O
(	O
Cambridge	O
,	O
MA	O
).	O

For	O
blocking	O
assays	O
,	O
rabbit	B-OG
polyclonal	O
anti	O
-	O
S100A9	B-GP
and	O
anti	O
-	O
S100A8	B-GP
were	O
generously	O
supplied	O
by	O
Dr	O
Philippe	O
A	O
.	O

Tessier	O
,	O
and	O
blocking	O
antibody	B-GP
against	O
CD11b	B-GP
(	O
BioLegend	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
was	O
used	O
at	O
different	O
dilutions	O
as	O
indicated	O
.	O

Rabbit	B-OG
serum	O
was	O
obtained	O
from	O
Jackson	O
Laboratories	O
(	O
Jackson	O
ImmunoResearch	O
,	O
West	O
Grove	O
,	O
PA	O
).	O

Cell	O
isolation	O
and	O
culturing	O

Blood	O
neutrophils	O
were	O
isolated	O
from	O
fresh	O
buffy	O
coats	O
obtained	O
from	O
healthy	O
donors	O
.	O

RBCs	O
were	O
sedimented	O
by	O
adding	O
6	O
%	O
hetastarch	O
in	O
0	O
.	O
9	O
%	O
NaCl	O
solution	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
Vancouver	O
,	O
Canada	O
)	O
and	O
kept	O
at	O
25	O
°	O
C	O
for	O
up	O
to	O
45	O
min	O
.	O

The	O
leukocyte	O
-	O
rich	O
upper	O
layer	O
of	O
the	O
suspension	O
was	O
then	O
collected	O
and	O
centrifuged	O
on	O
a	O
density	O
gradient	O
with	O
Ficoll	O
-	O
Paque	O
(	O
Amersham	O
Biosciences	O
,	O
Uppsala	O
,	O
Sweden	O
).	O

Residual	O
erythrocytes	O
were	O
removed	O
by	O
hypotonic	O
lysis	O
.	O

Neutrophils	O
were	O
maintained	O
in	O
suspension	O
,	O
at	O
different	O
concentrations	O
as	O
indicated	O
,	O
in	O
RPMI	O
1640	O
medium	O
,	O
1	O
%	O
L	O
-	O
glutamine	O
,	O
and	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
,	O
in	O
24	O
-	O
well	O
plates	O
at	O
37	O
°	O
C	O
,	O
in	O
a	O
humidified	O
incubator	O
containing	O
5	O
%	O
CO2	O
.	O

Cells	O
were	O
>	O
95	O
%	O
neutrophils	O
as	O
determined	O
by	O
morphological	O
analysis	O
and	O
>	O
99	O
%	O
viable	O
as	O
determined	O
by	O
Trypan	O
blue	O
dye	O
exclusion	O

Apoptosis	O
assessment	O

Apoptosis	O
assessment	O
was	O
performed	O
as	O
previously	O
described	O
[	O
27	O
]	O
(	O
For	O
detailed	O
method	O
see	O
–	O
Methods	O
S1	O
).	O

Supernatant	O
transfer	O

Neutrophils	O
were	O
suspended	O
at	O
concentrations	O
of	O
either	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
or	O
16	O
×	O
106	O
/	O
ml	O
,	O
for	O
different	O
times	O
as	O
indicated	O
,	O
at	O
37	O
°	O
C	O
/	O
5	O
%	O
CO2	O
.	O

After	O
culturing	O
,	O
the	O
supernatants	O
of	O
the	O
high	O
concentration	O
were	O
collected	O
and	O
added	O
to	O
fresh	O
neutrophils	O
from	O
the	O
same	O
donor	O
at	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
and	O
vice	O
versa	O
.	O

The	O
neutrophils	O
were	O
then	O
allowed	O
to	O
undergo	O
constitutive	O
spontaneous	O
PCD	O
and	O
apoptosis	O
was	O
detected	O
as	O
described	O
.	O

Transmission	O
electron	O
microscopy	O

Cells	O
were	O
fixed	O
in	O
2	O
%	O
glutaraldedyde	O
in	O
cacodylate	O
buffer	O
(	O
0	O
.	O
1M	O
,	O
PH	O
7	O
.	O
2	O
–	O
7	O
.	O
4	O
)	O
and	O
washed	O
three	O
times	O
in	O
the	O
same	O
buffer	O
.	O

Cells	O
were	O
then	O
postfixed	O
in	O
1	O
%	O
OSO4	O
for	O
1	O
h	O
at	O
room	O
temperature	O
,	O
washed	O
in	O
cacodylate	O
buffer	O
,	O
dedydrated	O
in	O
gradient	O
series	O
of	O
ethanol	O
(	O
25	O
%,	O
50	O
%,	O
75	O
%,	O
95	O
%,	O
100	O
%×	O
2	O
),	O
treated	O
with	O
propylene	O
-	O
oxide	O
for	O
20	O
min	O
(	O
2	O
changes	O
),	O
and	O
embedded	O
in	O
Araldite	O
Resin	O
.	O

Thin	O
sections	O
were	O
prepared	O
with	O
an	O
ultramicrotom	O
and	O
examined	O
at	O
an	O
accelerated	O
voltage	O
of	O
100KW	O
by	O
transmission	O
electron	O
microscope	O
(	O
CM12	O
,	O
Philips	O
,	O
Eindhoeven	O
,	O
The	O
Netherlands	O
).	O

Proteomic	O
(	O
SDS	O
-	O
PAGE	O
and	O
MS	O
)	O
and	O
Western	O
blotting	O

Proteomic	O
(	O
SDS	O
-	O
PAGE	O
and	O
MS	O
)	O
and	O
Western	O
blotting	O
were	O
performed	O
as	O
previously	O
described	O
[	O
28	O
]	O
(	O
For	O
detailed	O
method	O
see	O
–	O
Methods	O
S1	O
).	O

Transfection	O

The	O
two	O
cell	O
lines	O
,	O
Chinese	B-OG
hamster	I-OG
ovary	O
(	O
CHO	O
),	O
and	O
CHO	O
stably	O
transfected	O
with	O
complement	B-GP
receptor	I-GP
CR3	B-GP
,	O
were	O
kindly	O
provided	O
by	O
Drs	O
.	O

R	O
.	O
R	O
.	O

Ingalls	O
and	O
D	O
.	O
T	O
.	O

Golenbock	O
,	O
Boston	O
Medical	O
Center	O
,	O
Boston	O
,	O
MA	O
.	O

Leukocyte	B-DS
adhesion	I-DS
deficiency	I-DS
patients	O
and	O
controls	O

LAD	B-DS
patients	O
signed	O
an	O
informed	O
consent	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Hadassah	O
-	O
Hebrew	O
University	O
Medical	O
Center	O
.	O

Controls	O
consisted	O
of	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
donors	O
,	O
who	O
signed	O
an	O
informed	O
consent	O
.	O

Blood	O
(	O
10	O
ml	O
)	O
from	O
healthy	O
donors	O
and	O
heparinized	O
blood	O
(	O
10	O
ml	O
)	O
from	O
patients	O
was	O
drawn	O
and	O
evaluated	O
on	O
the	O
same	O
day	O
.	O

Detection	O
of	O
intracellular	O
phosphorylated	O
ERK	B-GP
by	O
flow	O
cytometry	O

For	O
the	O
assessment	O
of	O
phosphorylation	O
of	O
the	O
ERK	B-GP
,	O
freshly	O
isolated	O
neutrophils	O
were	O
treated	O
as	O
indicated	O
and	O
prepared	O
for	O
intracellular	O
staining	O
.	O

Cells	O
were	O
washed	O
with	O
PBS	O
,	O
fixed	O
with	O
2	O
%	O
formaldehyde	O
for	O
10	O
min	O
at	O
37	O
°	O
C	O
,	O
and	O
permeabilized	O
with	O
90	O
%	O
methanol	O
for	O
30	O
min	O
on	O
ice	O
.	O

Cells	O
then	O
were	O
rinsed	O
and	O
incubated	O
for	O
10	O
min	O
at	O
RT	O
in	O
PBS	O
containing	O
0	O
.	O
5	O
%	O
BSA	B-GP
(	O
for	O
blocking	O
),	O
and	O
stained	O
with	O
either	O
mouse	B-OG
anti	O
-	O
human	B-OG
phospho	O
-	O
p44	B-GP
/	O
42	O
MAPK	B-GP
alexa	O
fluor	O
488	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
or	O
isotype	O
control	O
mouse	B-OG
IgG1	B-GP
alexa	O
fluor	O
488	O
(	O
BioLegend	O
).	O

Statistical	O
analysis	O

The	O
Student	O
'	O
s	O
t	O
test	O
and	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
were	O
used	O
to	O
compare	O
mean	O
data	O
.	O

The	O
Kolmogorov	O
-	O
Smirnov	O
test	O
was	O
used	O
to	O
analyze	O
flow	O
cytometry	O
results	O
.	O

Differences	O
were	O
considered	O
statistically	O
significant	O
for	O
p	O
<	O
0	O
.	O
05	O
.	O

Results	O

The	O
effect	O
of	O
cell	O
concentration	O
on	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O

We	O
assumed	O
constitutive	O
spontaneous	O
PCD	O
requires	O
one	O
or	O
more	O
autoregulatory	O
negative	O
feedback	O
mechanisms	O
exerted	O
by	O
dying	O
neutrophils	O
that	O
affect	O
survival	O
rates	O
of	O
the	O
remaining	O
cells	O
(	O
Fig	O
.	O
1	O
).	O

Without	O
this	O
effect	O
,	O
one	O
might	O
assume	O
that	O
PCD	O
increases	O
at	O
higher	O
concentrations	O
due	O
to	O
competition	O
for	O
nutrition	O
and	O
other	O
ingredients	O
.	O

We	O
designed	O
an	O
experiment	O
to	O
examine	O
the	O
effect	O
of	O
various	O
cell	O
concentrations	O
in	O
the	O
physiological	O
range	O
(	O
peripheral	O
blood	O
neutrophil	O
concentration	O
∼	O
2	O
−	O
6	O
×	O
106	O
/	O
ml	O
)	O
on	O
the	O
constitutive	O
spontaneous	O
PCD	O
rate	O
.	O

A	O
higher	O
apoptotic	O
cell	O
concentration	O
had	O
a	O
protective	O
anti	O
-	O
apoptotic	O
effect	O
,	O
and	O
the	O
rate	O
of	O
neutrophil	O
PCD	O
was	O
inversely	O
proportional	O
to	O
cell	O
concentration	O
,	O
indicating	O
an	O
anti	O
-	O
apoptotic	O
effect	O
(	O
Fig	O
.	O
2A	O
).	O

Whereas	O
following	O
12h	O
of	O
spontaneous	O
constitutive	O
PCD	O
only	O
5	O
%	O
of	O
cells	O
were	O
still	O
alive	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
neutrophils	O
/	O
ml	O
,	O
in	O
conditions	O
of	O
32	O
fold	O
concentration	O
,	O
at	O
16	O
×	O
106	O
neutrophils	O
/	O
ml	O
,	O
more	O
than	O
40	O
%	O
of	O
the	O
cells	O
were	O
still	O
alive	O
,	O
as	O
shown	O
by	O
Annexin	B-GP
V	I-GP
and	O
PI	O
negative	O
staining	O
(	O
Fig	O
.	O
2B	O
)	O
and	O
verified	O
by	O
mitochondrial	O
potential	O
loss	O
studies	O
(	O
not	O
shown	O
),	O
both	O
methods	O
of	O
apoptosis	O
detection	O
indicated	O
early	O
apoptosis	O
state	O
.	O

This	O
phenomenon	O
was	O
further	O
emphasized	O
using	O
cell	O
count	O
.	O

There	O
was	O
loss	O
of	O
over	O
50	O
%	O
of	O
cells	O
through	O
constitutive	O
spontaneous	O
PCD	O
at	O
concentrations	O
of	O
­­­­	O
0	O
.	O
5x106	O
/	O
ml	O
for	O
12h	O
(	O
Fig	O
.	O
2C	O
),	O
and	O
this	O
loss	O
decreased	O
in	O
proportion	O
to	O
increasing	O
cell	O
concentrations	O
up	O
to	O
16x106	O
/	O
ml	O
.	O

At	O
concentrations	O
above	O
16x106	O
/	O
ml	O
,	O
there	O
was	O
a	O
decline	O
in	O
cell	O
number	O
and	O
a	O
prodeath	O
effect	O
,	O
probably	O
as	O
a	O
result	O
of	O
competition	O
for	O
nutrition	O
and	O
other	O
ingredients	O
.	O

Constitutive	O
spontaneous	O
neutrophil	O
PCD	O
.	O

A	O
.	O
Kinetics	O
of	O
spontaneous	O
constitutive	O
neutrophil	O
PCD	O
.	O

Neutrophils	O
were	O
isolated	O
and	O
allowed	O
to	O
undergo	O
spontaneous	O
constitutive	O
PCD	O
at	O
a	O
concentration	O
of	O
1	O
×	O
106	O
/	O
ml	O
.	O

Samples	O
were	O
obtained	O
at	O
the	O
indicated	O
intervals	O
,	O
and	O
the	O
apoptosis	O
rate	O
was	O
measured	O
using	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
PI	O
staining	O
.	O
B	O
.	O
Transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
of	O
spontaneous	O
constitutive	O
neutrophil	O
PCD	O
.	O

Morphology	O
of	O
viable	O
or	O
early	O
apoptotic	O
(	O
white	O
arrow	O
)	O
and	O
apoptotic	O
(	O
black	O
arrows	O
)	O
neutrophils	O
is	O
shown	O
.	O

Apoptotic	O
cells	O
show	O
the	O
typical	O
morphology	O
of	O
condensed	O
cytoplasm	O
and	O
chromatin	O
.	O

Cells	O
were	O
prepared	O
for	O
TEM	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O
C	O
.	O
Inhibition	O
of	O
spontaneous	O
constitutive	O
neutrophil	O
PCD	O
by	O
pan	O
-	O
caspase	B-GP
inhibitor	O
zVAD	O
-	O
fmk	O
.	O

Sample	O
dot	O
plots	O
of	O
AnnexinV	B-GP
-	O
PI	O
staining	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
for	O
14	O
h	O
at	O
a	O
concentration	O
of	O
1	O
×	O
106	O
/	O
ml	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
µM	O
Zvad	O
-	O
fmk	O
.	O

Pan	O
-	O
caspase	B-GP
inhibition	O
rescued	O
cells	O
from	O
apoptotic	O
death	O
and	O
viable	O
cells	O
are	O
increased	O
from	O
19	O
to	O
49	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Data	O
are	O
representative	O
of	O
3	O
or	O
more	O
experiments	O
.	O

Spontaneous	O
constitutive	O
neutrophil	O
PCD	O
is	O
cell	O
concentration	O
-	O
dependent	O
.	O

A	O
.	O
Neutrophils	O
underwent	O
spontaneous	O
constitutive	O
PCD	O
for	O
12	O
h	O
at	O
cell	O
concentrations	O
ranging	O
from	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
up	O
to	O
50	O
×	O
106	O
/	O
ml	O
.	O

(	O
The	O
physiological	O
blood	O
concentration	O
is	O
2	O
−	O
6	O
×	O
106	O
/	O
ml	O
.)	O
Apoptosis	O
was	O
assessed	O
by	O
AnnexinV	B-GP
-	O
FITC	O
and	O
PI	O
staining	O
,	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Data	O
represents	O
the	O
mean	O
±	O
SD	O
of	O
3	O
experiments	O
.	O
B	O
.	O
Sample	O
dot	O
plots	O
of	O
AnnexinV	B-GP
-	O
PI	O
staining	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
for	O
12	O
h	O
in	O
(	O
a	O
)	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
,	O
and	O
(	O
b	O
)	O
16	O
×	O
106	O
/	O
ml	O
.	O

The	O
percentage	O
of	O
viable	O
,	O
early	O
(	O
AnnexinV	B-GP
+/	O
PI	O
−)	O
and	O
late	O
(	O
AnnexinV	B-GP
+/	O
PI	O
+)	O
apoptotic	O
cells	O
is	O
indicated	O
within	O
the	O
respective	O
quadrants	O
.	O
C	O
.	O
Survival	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
,	O
based	O
on	O
cell	O
counts	O
.	O

Data	O
presented	O
is	O
the	O
mean	O
±	O
SD	O
of	O
3	O
experiments	O
.	O

Thus	O
,	O
at	O
physiological	O
concentrations	O
of	O
neutrophils	O
,	O
there	O
was	O
an	O
anti	O
-	O
apoptotic	O
effect	O
at	O
higher	O
neutrophil	O
concentrations	O
.	O

We	O
termed	O
this	O
a	O
“	O
community	O
effect	O
”	O
―	O
neutrophils	O
are	O
encouraged	O
to	O
live	O
longer	O
as	O
their	O
community	O
is	O
enlarged	O
.	O

Factors	O
mediating	O
the	O
community	O
effect	O
are	O
present	O
in	O
the	O
supernatant	O

In	O
order	O
to	O
determine	O
whether	O
the	O
factor	O
(	O
s	O
)	O
responsible	O
for	O
the	O
community	O
anti	O
-	O
apoptotic	O
effect	O
are	O
found	O
in	O
the	O
supernatant	O
,	O
we	O
exchanged	O
media	O
obtained	O
from	O
low	O
-	O
and	O
high	O
concentrations	O
of	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
.	O

The	O
supernatants	O
from	O
high	O
concentrations	O
were	O
collected	O
and	O
used	O
as	O
media	O
for	O
low	O
-	O
concentration	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
of	O
the	O
same	O
donor	O
,	O
and	O
the	O
supernatants	O
of	O
low	O
concentrations	O
were	O
used	O
as	O
media	O
for	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
at	O
high	O
cell	O
concentration	O
.	O

Media	O
based	O
on	O
high	O
-	O
concentration	O
PCD	O
donors	O
(	O
16	O
×	O
106	O
cells	O
/	O
ml	O
)	O
rescued	O
cells	O
undergoing	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
at	O
low	O
concentration	O
(	O
0	O
.	O
5	O
×	O
106	O
cells	O
/	O
ml	O
)	O
from	O
apoptosis	O
,	O
as	O
compared	O
with	O
normal	O
medium	O
(	O
Fig	O
.	O
3A	O
).	O

High	O
-	O
concentration	O
medium	O
increased	O
the	O
rate	O
of	O
viable	O
cells	O
from	O
9	O
%	O
(	O
upper	O
left	O
panel	O
,	O
Fig	O
.	O
3B	O
)	O
to	O
31	O
%	O
(	O
upper	O
right	O
panel	O
,	O
Fig	O
.	O
3B	O
).	O

In	O
the	O
opposite	O
experiment	O
,	O
low	O
-	O
concentration	O
media	O
had	O
no	O
effect	O
on	O
survival	O
in	O
high	O
cell	O
concentration	O
samples	O
(	O
left	O
and	O
right	O
lower	O
panels	O
,	O
Fig	O
.	O
3B	O
).	O

All	O
these	O
experiments	O
were	O
based	O
on	O
at	O
least	O
three	O
experiments	O
each	O
and	O
results	O
with	O
Annexin	B-GP
V	I-GP
were	O
verified	O
using	O
mitochondrial	O
potential	O
loss	O
studies	O
.	O

Identification	O
of	O
candidate	O
molecules	O
that	O
induce	O
the	O
community	O
effect	O
.	O

A	O
.	O
Supernatant	O
of	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
high	O
concentrations	O
has	O
rescued	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
from	O
apoptosis	O
at	O
low	O
concentrations	O
,	O
and	O
improved	O
their	O
survival	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Data	O
is	O
representative	O
of	O
3	O
experiments	O
.	O
B	O
.	O
Representative	O
dot	O
plot	O
of	O
supernatant	O
transfer	O
assay	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
AnnexinV	B-GP
and	O
PI	O
staining	O
of	O
neutrophils	O
after	O
12	O
h	O
of	O
spontaneous	O
constitutive	O
PCD	O
.	O

The	O
transfer	O
assay	O
was	O
performed	O
as	O
follows	O
:	O
neutrophils	O
underwent	O
spontaneous	O
constitutive	O
PCD	O
at	O
low	O
(	O
a	O
,	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
)	O
or	O
high	O
(	O
c	O
,	O
16	O
×	O
106	O
/	O
ml	O
)	O
concentration	O
for	O
12	O
h	O
.	O

The	O
supernatant	O
of	O
the	O
cells	O
incubated	O
at	O
high	O
concentrations	O
was	O
collected	O
and	O
used	O
as	O
media	O
for	O
neutrophils	O
undergoing	O
constitutive	O
spontaneous	O
PCD	O
at	O
low	O
concentrations	O
(	O
b	O
),	O
and	O
the	O
supernatant	O
of	O
the	O
cells	O
incubated	O
at	O
low	O
concentrations	O
was	O
collected	O
and	O
used	O
for	O
neutrophils	O
undergoing	O
constitutive	O
spontaneous	O
PCD	O
at	O
high	O
concentrations	O
(	O
d	O
).	O
C	O
.	O
SDS	O
-	O
PAGE	O
of	O
differentially	O
displayed	O
proteins	O
from	O
high	O
-	O
and	O
low	O
-	O
concentration	O
spontaneous	O
constitutive	O
PCD	O
.	O

The	O
supernatants	O
of	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
high	O
-	O
and	O
low	O
concentrations	O
were	O
collected	O
,	O
and	O
the	O
proteins	O
were	O
purified	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Protein	O
samples	O
were	O
electrophorized	O
and	O
stained	O
with	O
Coomassie	O
,	O
as	O
shown	O
.	O

Two	O
proteins	O
,	O
∼	O
14	O
KD	O
and	O
∼	O
10	O
KD	O
,	O
were	O
identified	O
in	O
the	O
supernatant	O
of	O
cells	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
high	O
concentrations	O
(	O
16	O
×	O
106	O
/	O
ml	O
).	O

These	O
results	O
suggest	O
that	O
in	O
the	O
presence	O
of	O
high	O
neutrophil	O
concentrations	O
,	O
anti	O
-	O
apoptotic	O
factor	O
(	O
s	O
)	O
are	O
secreted	O
and	O
provide	O
a	O
survival	O
signal	O
to	O
the	O
viable	O
neutrophil	O
community	O
.	O

Proteomic	O
analysis	O
of	O
the	O
supernatants	O
and	O
identification	O
of	O
S100A8	B-GP
and	O
S100A9	B-GP
as	O
candidate	O
molecules	O
for	O
mediation	O
of	O
the	O
community	O
anti	O
-	O
apoptotic	O
signal	O

We	O
used	O
a	O
differentially	O
displayed	O
proteomic	O
approach	O
,	O
as	O
we	O
have	O
previously	O
described	O
[	O
28	O
],	O
to	O
search	O
for	O
secreted	O
factor	O
(	O
s	O
)	O
in	O
the	O
supernatant	O
that	O
may	O
be	O
responsible	O
for	O
the	O
“	O
community	O
effect	O
”	O
on	O
neutrophil	O
survival	O
.	O

The	O
secreted	O
proteomes	O
of	O
neutrophils	O
undergoing	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
at	O
high	O
concentrations	O
(	O
16	O
×	O
106	O
/	O
ml	O
)	O
and	O
low	O
concentrations	O
(	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
)	O
were	O
collected	O
and	O
compared	O
by	O
SDS	O
-	O
PAGE	O
and	O
Coomassie	O
staining	O
.	O

Differentially	O
expressed	O
proteins	O
were	O
further	O
analyzed	O
by	O
mass	O
spectrometry	O
(	O
MS	O
).	O

Expression	O
of	O
two	O
proteins	O
,	O
∼	O
10	O
KD	O
and	O
∼	O
14KD	O
,	O
represented	O
the	O
primary	O
difference	O
between	O
the	O
supernatants	O
(	O
Fig	O
.	O
3C	O
).	O

Both	O
were	O
expressed	O
at	O
significantly	O
greater	O
levels	O
in	O
supernatant	O
of	O
cells	O
cultured	O
at	O
high	O
neutrophil	O
concentrations	O
,	O
versus	O
supernatant	O
of	O
cells	O
cultured	O
at	O
low	O
concentrations	O
,	O
despite	O
protein	O
normalization	O
according	O
to	O
cell	O
number	O
and	O
equal	O
protein	O
loading	O
in	O
the	O
gel	O
.	O

Proteins	O
were	O
further	O
identified	O
by	O
MS	O
as	O
S100A8	B-GP
and	O
S100A9	B-GP
,	O
as	O
the	O
best	O
candidates	O
for	O
the	O
community	O
effect	O
(	O
Table	O
1	O
).	O

The	O
experimental	O
approach	O
was	O
designed	O
to	O
use	O
2D	O
gel	O
;	O
however	O
,	O
1D	O
gel	O
identified	O
with	O
high	O
certainty	O
two	O
candidate	O
proteins	O
that	O
were	O
chosen	O
for	O
further	O
functional	O
studies	O
.	O

Table	O
1	O
.	O
Proteins	O
identified	O
by	O
mass	O
spectrometry	O
.	O

Peptide	O
sequence	O

Protein	O
score	O
(	O
Mowse	O
)	O

Identified	O
protein	O

Remarks	O

MTCKMSQLER	O
NIETIINTFH	O
QYSVKLGHPD	O
TLNQGEFKEL	O
VRKDLQNFLK	O
KENKNEKVIE	O
HIMEDLDTNA	O
DKQLSFEEFI	O
MLMARLTWAS	O
HEKMHEGDEG	O
PGHHHKPGLG	O
EGTP	O

330	O

S100A9	B-GP

Reported	O
role	O
in	O
inflammation	O

MLTELEKALN	O
SIIDVYHKYS	O
LIKGNFHAVY	O
RDDLKKLLET	O
ECPQYIRKKG	O
ADVWFKELDI	O
NTDGAVNFQE	O
FLILVIKMAW	O
QPTKKAMKKA	O
TKSS	O

458	O

S100A8	B-GP

Reported	O
role	O
in	O
inflammation	O

MVHLTPEEKS	O
AVTALWGKVN	O
VDEVGGEALG	O
RLLVVYPWTQ	O
RFFESFGDLS	O
TPDAVMGNPK	O
VKAHGKKVLG	O
AFSDGLAHLD	O
NLKGTFATLS	O
ELHCDKLHVD	O
PENFRLLGNV	O
LVCVLAHHFG	O
KKFTPPVQAA	O
YQKVVAGVAN	O
ALAHKYH	O

207	O

beta	B-GP
globin	I-GP
chain	O
variant	O

Beta	B-GP
globin	I-GP
chain	O

VLSPADKTNV	O
KAAWGKVGAH	O
AGEYGAEALE	O
RMFLSFPTTK	O
TYFPHFDLSH	O
GSAQVKGHGK	O
KVADALTNAV	O
AHVDDMPNAL	O
SALSDLHAHK	O
LRVDPWNFKL	O
LSHCLLVTLA	O
AHLPAEFTPA	O
VHASLDKFLA	O
SVSTVLTSKY	O
R	O

94	O

Chain	O
C	O
,	O
T	O
State	O
Human	B-OG
Hemoglobin	B-GP
[	O
alpha	O
V96w	O
]	O

Hemoglobin	B-GP
chain	O

RRPDFCLEPP	O
YTGPCKARII	O
RYFYNAKAGL	O
CQTFVYGGCR	O
AKRNNFKSAE	O
DCMRTCGGA	O

113	O

Aprotinin	B-GP

Protease	B-GP
inhibitor	O
(	O
synthetic	O
)	O

Analysis	O
of	O
proteins	O
identified	O
by	O
mass	O
spectrometry	O
.	O

Sequences	O
corresponding	O
to	O
the	O
identified	O
peptides	O
are	O
bolded	O
.	O

Score	O
was	O
based	O
on	O
molecular	O
weight	O
search	O
(	O
MOWSE	O
)	O
peptide	O
-	O
mass	O
database	O
.	O

The	O
results	O
identified	O
S100A8	B-GP
and	O
S100A9	B-GP
as	O
candidate	O
proteins	O
.	O

Functional	O
studies	O
suggest	O
that	O
S100A8	B-GP
-	O
9	O
mediates	O
the	O
community	O
effect	O

We	O
sought	O
to	O
verify	O
S100A8	B-GP
and	O
A9	B-GP
mediation	O
of	O
the	O
community	O
anti	O
-	O
apoptotic	O
effect	O
using	O
recombinant	O
human	B-OG
S100A8	B-GP
and	O
A9	B-GP
(	O
kindly	O
provided	O
by	O
Philippe	O
A	O
.	O

Tessier	O
,	O
Laval	O
University	O
,	O
Quebec	O
,	O
Canada	O
)	O
added	O
to	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
.	O

Increased	O
S100A9	B-GP
and	O
S100A8	B-GP
/	O
9	O
levels	O
had	O
a	O
dramatic	O
rescue	O
effect	O
on	O
the	O
number	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
low	O
cell	O
concentrations	O
(*	O
p	O
<	O
0	O
.	O
05	O
),	O
paralleling	O
the	O
rescue	O
effect	O
of	O
the	O
high	O
cell	O
concentration	O
supernatant	O
(	O
Fig	O
.	O
4A	O
).	O

Survival	O
increased	O
by	O
more	O
than	O
150	O
%±	O
35	O
%	O
in	O
the	O
presence	O
of	O
5	O
µg	O
/	O
ml	O
of	O
S100A8	B-GP
/	O
9	O
,	O
as	O
measured	O
by	O
Annexin	B-GP
V	I-GP
and	O
PI	O
(**	O
p	O
<	O
0	O
.	O
02	O
).	O

The	O
survival	O
effect	O
of	O
S100A9	B-GP
and	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
was	O
more	O
prominent	O
compared	O
to	O
S100A9	B-GP
alone	O
.	O

Only	O
S100A9	B-GP
had	O
an	O
effect	O
already	O
at	O
a	O
concentration	O
of	O
1	O
µg	O
/	O
ml	O
.	O

Nonetheless	O
,	O
S100A8	B-GP
in	O
higher	O
concentrations	O
of	O
2	O
and	O
5	O
µg	O
/	O
ml	O
also	O
had	O
a	O
significant	O
rescue	O
effect	O
(	O
Fig	O
.	O
4A	O
).	O

To	O
further	O
verify	O
the	O
anti	O
-	O
apoptotic	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
,	O
we	O
measured	O
mitochondrial	O
transmemebrane	O
potential	O
as	O
an	O
additional	O
early	O
PCD	O
evaluation	O
,	O
demonstrating	O
a	O
perfect	O
correlation	O
to	O
the	O
Annexin	B-GP
V	I-GP
-	O
PI	O
measurements	O
(	O
Fig	O
.	O
4B	O
).	O

Effect	O
of	O
S100A9	B-GP
and	O
S100A8	B-GP
on	O
neutrophil	O
apoptosis	O
.	O

A	O
.	O
S100A9	B-GP
and	O
S100A8	B-GP
add	O
-	O
in	O
experiments	O
.	O

Varying	O
concentrations	O
of	O
S100A9	B-GP
,	O
S100A8	B-GP
,	O
and	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
were	O
added	O
to	O
supernatants	O
of	O
neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
.	O

After	O
10	O
hours	O
apoptosis	O
was	O
evaluated	O
using	O
Annexin	B-GP
V	I-GP
-	O
PI	O
and	O
mitochondrial	O
staining	O
.	O

Data	O
is	O
presented	O
as	O
mean	O
±	O
SD	O
of	O
Annexin	B-GP
V	I-GP
-	O
PI	O
staining	O
(*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
<	O
0	O
.	O
02	O
).	O
B	O
.	O
S100A9	B-GP
and	O
S100A8	B-GP
add	O
-	O
in	O
experiments	O
.	O

A	O
representative	O
sample	O
of	O
Annexin	B-GP
V	I-GP
-	O
PI	O
and	O
mitochondrial	O
staining	O
.	O

Neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
without	O
(	O
a	O
and	O
c	O
)	O
or	O
with	O
(	O
b	O
and	O
d	O
)	O
the	O
addition	O
of	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
.	O

Cells	O
were	O
stained	O
either	O
with	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
(	O
a	O
and	O
b	O
)	O
or	O
with	O
DiOC6	O
(	O
c	O
and	O
d	O
),	O
as	O
well	O
as	O
PI	O
(	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
)	O
and	O
assessed	O
by	O
flow	O
cytometry	O
.	O

Dot	O
plots	O
are	O
representative	O
of	O
6	O
experiments	O
.	O
C	O
.	O
The	O
effect	O
of	O
anti	O
-	O
S100A8	B-GP
and	O
A9	B-GP
on	O
add	O
-	O
in	O
experiments	O
.	O

Neutrophils	O
undergoing	O
spontaneous	O
constitutive	O
PCD	O
at	O
a	O
concentration	O
of	O
0	O
.	O
5	O
×	O
106	O
/	O
ml	O
for	O
12h	O
,	O
with	O
rabbit	B-OG
polyclonal	O
antibody	B-GP
dilutions	O
of	O
1	O
∶	O
100	O
,	O
1	O
∶	O
1000	O
,	O
and	O
1	O
∶	O
10	O
,	O
000	O
against	O
S100A9	B-GP
and	O
S100A8	B-GP
,	O
were	O
then	O
treated	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
complex	O
.	O

Rabbit	B-OG
serum	O
at	O
the	O
same	O
dilutions	O
of	O
1	O
∶	O
100	O
,	O
1	O
∶	O
1000	O
,	O
and	O
1	O
∶	O
10	O
,	O
000	O
was	O
used	O
as	O
a	O
control	O
.	O

Apoptosis	O
was	O
assessed	O
using	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
PI	O
staining	O
.	O

Percentages	O
of	O
viable	O
,	O
early	O
-,	O
and	O
late	O
apoptotic	O
cells	O
are	O
indicated	O
within	O
the	O
respective	O
quadrants	O
.	O

Dot	O
plots	O
are	O
representative	O
of	O
6	O
experiments	O
.	O

We	O
sought	O
to	O
verify	O
whether	O
S100A9	B-GP
and	O
S100A8	B-GP
/	O
9	O
effects	O
are	O
blocked	O
with	O
specific	O
antibodies	B-GP
,	O
using	O
rabbit	B-OG
polyclonal	O
antibodies	B-GP
raised	O
against	O
human	B-OG
S100A8	B-GP
or	O
S100A9	B-GP
.	O

Antisera	O
were	O
used	O
at	O
a	O
range	O
of	O
dilutions	O
between	O
1	O
/	O
10	O
and	O
1	O
/	O
10	O
,	O
000	O
,	O
as	O
indicated	O
.	O

Adding	O
the	O
antibodies	B-GP
reduced	O
neutrophil	O
survival	O
by	O
30	O
−	O
40	O
%	O
in	O
various	O
dilutions	O
(	O
Fig	O
.	O
4C	O
),	O
compared	O
to	O
control	O
antibodies	B-GP
,	O
and	O
induced	O
accelerated	O
PCD	O
similar	O
to	O
that	O
seen	O
in	O
spontaneous	O
constitutive	O
PCD	O
in	O
low	O
cell	O
concentration	O
supernatants	O
.	O

Mitochondrial	O
transmemebrane	O
potential	O
as	O
an	O
additional	O
early	O
PCD	O
evaluation	O
,	O
demonstrated	O
a	O
perfect	O
correlation	O
to	O
the	O
Annexin	B-GP
V	I-GP
-	O
PI	O
measurements	O
.	O

This	O
further	O
supports	O
a	O
role	O
for	O
S100A8	B-GP
/	O
9	O
as	O
the	O
main	O
factor	O
triggering	O
the	O
community	O
anti	O
-	O
apoptotic	O
effect	O
.	O

S100A8	B-GP
/	O
9	O
does	O
not	O
mediate	O
the	O
community	O
effect	O
via	O
McL1	B-GP
,	O
A1	B-GP
,	O
the	O
bcl	B-GP
-	I-GP
2	I-GP
protein	O
family	O
,	O
or	O
survivin	B-GP

We	O
examined	O
the	O
expression	O
of	O
different	O
members	O
of	O
the	O
PCD	O
intrinsic	O
pathway	O
,	O
focusing	O
on	O
those	O
known	O
to	O
be	O
important	O
in	O
neutrophil	O
PCD	O
.	O

McL1	B-GP
,	O
an	O
anti	O
-	O
apoptotic	O
member	O
,	O
was	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
(	O
see	O
Figure	O
S3	O
),	O
and	O
expression	O
was	O
still	O
detected	O
during	O
spontaneous	O
constitutive	O
apoptosis	O
.	O

Adding	O
S100A8	B-GP
/	O
9	O
did	O
not	O
change	O
McL1	B-GP
expression	O
.	O

A1	B-GP
protein	O
has	O
also	O
been	O
found	O
to	O
be	O
expressed	O
in	O
neutrophils	O
[	O
13	O
],	O
[	O
15	O
].	O

We	O
found	O
that	O
A1	B-GP
was	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
,	O
with	O
expression	O
dramatically	O
decreased	O
during	O
constitutive	O
spontaneous	O
PCD	O
(	O
see	O
Figure	O
S3	O
).	O

Adding	O
S100A8	B-GP
/	O
9	O
did	O
not	O
prevent	O
decreased	O
A1	B-GP
expression	O
.	O

Bclxl	B-GP
was	O
found	O
to	O
be	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
.	O

Expression	O
was	O
neither	O
decreased	O
by	O
constitutive	O
spontaneous	O
PCD	O
,	O
nor	O
increased	O
by	O
adding	O
S100A8	B-GP
/	O
9	O
.	O

We	O
also	O
examined	O
the	O
expression	O
of	O
Bcl2	B-GP
and	O
survivin	B-GP
proteins	O
.	O

These	O
two	O
proteins	O
were	O
not	O
expressed	O
by	O
freshly	O
isolated	O
neutrophils	O
or	O
during	O
induction	O
of	O
constitutive	O
spontaneous	O
PCD	O
,	O
which	O
is	O
consistent	O
with	O
observations	O
that	O
peripheral	O
blood	O
neutrophils	O
don	O
'	O
t	O
express	O
these	O
two	O
proteins	O
[	O
11	O
−	O
14	O
],	O
.	O

In	O
conclusion	O
,	O
we	O
could	O
not	O
identify	O
an	O
anti	O
-	O
apoptotic	O
mechanism	O
in	O
the	O
main	O
intrinsic	O
pathway	O
players	O
of	O
neutrophil	O
PCD	O
.	O

The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
involves	O
the	O
MEK	B-GP
-	O
ERK	B-GP
signaling	O
pathway	O
,	O
and	O
is	O
partially	O
mediated	O
through	O
TLR4	B-GP
and	O
the	O
integrin	B-GP
CD11b	B-GP
/	O
CD18	B-GP

S100A8	B-GP
and	O
A9	B-GP
specific	O
receptors	O
have	O
not	O
yet	O
been	O
identified	O
.	O

However	O
,	O
Vogl	O
et	O
al	O
demonstrated	O
that	O
S100A8	B-GP
specifically	O
interacts	O
with	O
the	O
TLR4	B-GP
-	O
MD2	B-GP
complex	O
[	O
29	O
],	O
and	O
Newton	O
RA	O
et	O
al	O
suggested	O
that	O
a	O
pertusis	B-GP
toxin	I-GP
-	O
sensitive	O
G	B-GP
-	I-GP
coupled	I-GP
protein	I-GP
receptor	I-GP
could	O
be	O
the	O
S100A9	B-GP
receptor	I-GP
[	O
30	O
].	O

S100A8	B-GP
and	O
A9	B-GP
have	O
been	O
shown	O
to	O
exert	O
their	O
effects	O
via	O
CD36	B-GP
and	O
CD11b	B-GP
/	O
CD18	B-GP
(	O
Mac	B-GP
-	I-GP
1	I-GP
)	O
[	O
30	O
−	O
32	O
].	O
CD11b	B-GP
/	O
CD18	B-GP
is	O
well	O
expressed	O
in	O
freshly	O
isolated	O
neutrophils	O
,	O
but	O
CD36	B-GP
is	O
not	O
(	O
Fig	O
.	O
5A	O
,	O
upper	O
panel	O
).	O

Furthermore	O
,	O
CD11b	B-GP
/	O
CD18	B-GP
was	O
suggested	O
as	O
a	O
pro	O
-	O
apoptotic	O
integrin	B-GP
[	O
33	O
],	O
[	O
34	O
].	O

The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
is	O
mediated	O
through	O
CD11b	B-GP
/	O
CD18	B-GP
and	O
TLR4	B-GP
.	O

A	O
.	O
Expression	O
of	O
CD11b	B-GP
on	O
neutrophils	O
.	O

Upper	O
panel	O
.	O

Freshly	O
isolated	O
neutrophils	O
express	O
CD11b	B-GP
/	O
CD18	B-GP
(	O
isotype	O
control	O
is	O
shown	O
as	O
filled	O
histogram	O
and	O
anti	O
-	O
CD11b	B-GP
/	O
CD18	B-GP
-	O
PE	B-GP
in	O
dotted	O
line	O
,	O
middle	O
)	O
but	O
not	O
CD36	B-GP
(	O
left	O
).	O

Following	O
12	O
h	O
of	O
spontaneous	O
PCD	O
(	O
gray	O
line	O
,	O
middle	O
)	O
there	O
was	O
a	O
marked	O
decrease	O
in	O
the	O
expression	O
of	O
CD11b	B-GP
/	O
CD18	B-GP
in	O
comparison	O
to	O
freshly	O
isolated	O
neutrophils	O
.	O

Addition	O
of	O
S100A8	B-GP
/	O
9	O
resulted	O
in	O
two	O
different	O
cell	O
populations	O
:	O
high	O
and	O
low	O
-	O
CD11b	B-GP
/	O
CD18	B-GP
(	O
black	O
line	O
,	O
right	O
).	O

Lower	O
panel	O
.	O

Left	O
.	O

Correlation	O
between	O
CD11b	B-GP
and	O
phosphatidylserine	O
expression	O
demonstrates	O
that	O
when	O
neutrophils	O
become	O
apoptotic	O
they	O
downregulate	O
CD11b	B-GP
expression	O
.	O

Right	O
.	O

S100A8	B-GP
/	O
9	O
upregulates	O
CD11b	B-GP
expression	O
.	O
B	O
.	O
S100A8	B-GP
/	O
9	O
dramatically	O
increases	O
CD11b	B-GP
on	O
viable	O
cells	O
.	O

Viable	O
cells	O
(	O
R1	O
,	O
black	O
line	O
)	O
increase	O
CD11b	B-GP
expression	O
from	O
a	O
mean	O
fluorescence	O
of	O
552	O
to	O
1094	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Apoptotic	O
cells	O
(	O
R2	O
,	O
gray	O
line	O
)	O
still	O
maintain	O
some	O
of	O
this	O
effect	O
and	O
show	O
a	O
mean	O
fluorescence	O
of	O
473	O
,	O
compared	O
to	O
362	O
in	O
the	O
absence	O
of	O
S100A8	B-GP
/	O
9	O
.	O

Filled	O
histograms	O
represent	O
isotype	O
control	O
.	O

Neutrophils	O
were	O
harvested	O
after	O
12	O
h	O
spontaneous	O
constitutive	O
PCD	O
,	O
with	O
or	O
without	O
treatment	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
.	O

Histograms	O
are	O
representative	O
of	O
at	O
least	O
3	O
different	O
experiments	O
.	O
C	O
.	O
The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
anti	O
-	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

Upper	O
panel	O
.	O

Right	O
.	O

Neutrophils	O
were	O
incubated	O
for	O
12	O
h	O
and	O
treated	O
with	O
either	O
anti	O
-	O
CD11b	B-GP
or	O
the	O
isotype	O
control	O
IgG1	B-GP
before	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
complex	O
.	O

Integrin	B-GP
inhibition	O
reduced	O
the	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
40	O
−	O
100	O
%	O
in	O
comparison	O
with	O
the	O
isotype	O
control	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
average	O
of	O
6	O
experiments	O
is	O
presented	O
.	O

Lower	O
panel	O
.	O

A	O
representative	O
dot	O
plot	O
is	O
shown	O
.	O

Upper	O
panel	O
.	O

Left	O
.	O

S100A8	B-GP
/	O
9	O
binds	O
to	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

CHO	O
cells	O
transfected	O
with	O
CR3	B-GP
(	O
black	O
)	O
or	O
vector	O
(	O
gray	O
)	O
were	O
evaluated	O
for	O
S100A8	B-GP
/	O
9	O
binding	O
.	O

CR3	B-GP
-	O
ransfected	O
cells	O
bound	O
at	O
rates	O
almost	O
twofold	O
higher	O
than	O
CHO	O
control	O
cells	O
(	O
median	O
fluorescence	O
13	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
).	O

The	O
filled	O
curve	O
represents	O
isotype	O
control	O
;	O
the	O
histogram	O
is	O
representative	O
of	O
3	O
experiments	O
.	O
D	O
.	O
S100A8	B-GP
/	O
9	O
effect	O
on	O
neutrophils	O
from	O
a	O
CD11b	B-GP
/	O
CD18	B-GP
-	O
deficient	O
patient	O
.	O

Neutrophil	O
expression	O
of	O
CD11b	B-GP
from	O
a	O
healthy	O
control	O
and	O
a	O
patient	O
with	O
leukocyte	B-DS
adhesion	I-DS
deficiency	I-DS
is	O
shown	O
in	O
the	O
upper	O
panel	O
.	O

Spontaneous	O
constitutive	O
apoptosis	O
is	O
shown	O
in	O
the	O
lower	O
panel	O
,	O
together	O
with	O
the	O
S100A8	B-GP
/	O
9	O
effect	O
.	O

Neutrophils	O
were	O
isolated	O
from	O
a	O
CD11b	B-GP
-	O
deficient	O
patient	O
and	O
a	O
healthy	O
control	O
,	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
,	O
incubated	O
at	O
a	O
concentration	O
of	O
1	O
×	O
106	O
/	O
ml	O
and	O
allowed	O
to	O
undergo	O
spontaneous	O
constitutive	O
PCD	O
for	O
10	O
h	O
,	O
with	O
or	O
without	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
Annexin	B-GP
V	I-GP
-	O
PI	O
staining	O
.	O
E	O
.	O
The	O
survival	O
effect	O
induced	O
by	O
the	O
complex	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
pertussis	B-GP
toxin	I-GP
.	O
Bordetella	B-OG
pertussis	I-OG
toxin	O
at	O
100	O
and	O
500	O
ng	O
/	O
ml	O
were	O
added	O
to	O
neutrophils	O
45	O
min	O
before	O
adding	O
S100A8	B-GP
/	O
9	O
.	O

Neutrophils	O
then	O
were	O
allowed	O
to	O
undergo	O
constitutive	O
spontaneous	O
PCD	O
that	O
was	O
assessed	O
using	O
AnnexinV	B-GP
-	O
FITC	O
and	O
PI	O
staining	O
after	O
12	O
h	O
.	O

The	O
dot	O
plots	O
are	O
representative	O
of	O
3	O
experiments	O
.	O
F	O
.	O
The	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
anti	O
-	O
TLR4	B-GP
.	O

Neutrophils	O
were	O
incubated	O
for	O
10	O
h	O
and	O
treated	O
with	O
either	O
anti	O
-	O
TLR4	B-GP
or	O
the	O
isotype	O
control	O
IgG2a	B-GP
,	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Inhibition	O
of	O
TLR4	B-GP
abrogated	O
the	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
30	O
−	O
60	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
comparison	O
with	O
the	O
isotype	O
control	O
,	O
as	O
seen	O
in	O
upper	O
panel	O
.	O

The	O
upper	O
panel	O
is	O
presented	O
as	O
percentage	O
of	O
control	O
.	O

The	O
experiment	O
is	O
a	O
summary	O
of	O
four	O
experiments	O
(	O
upper	O
panel	O
)	O
with	O
representative	O
Plots	O
in	O
the	O
lower	O
panel	O
.	O

Following	O
spontaneous	O
constitutive	O
PCD	O
,	O
we	O
detected	O
a	O
homogeneous	O
decrease	O
in	O
neutrophil	O
expression	O
of	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

Gating	O
apoptotic	O
(	O
Annexin	B-GP
V	I-GP
-	O
positive	O
)	O
versus	O
nonapoptotic	O
(	O
Annexin	B-GP
V	I-GP
-	O
negative	O
)	O
cells	O
(	O
Fig	O
.	O
5B	O
)	O
revealed	O
higher	O
CD11b	B-GP
/	O
CD18	B-GP
expression	O
on	O
viable	O
-	O
versus	O
apoptotic	O
neutrophils	O
(	O
Fig	O
.	O
5A	O
−	O
B	O
).	O

Furthermore	O
,	O
adding	O
S100A8	B-GP
/	O
9	O
dramatically	O
upregulated	O
CD11b	B-GP
/	O
CD18	B-GP
,	O
establishing	O
a	O
new	O
subpopulation	O
with	O
very	O
high	O
expression	O
on	O
viable	O
cells	O
(	O
Fig	O
.	O
5A	O
−	O
B	O
).	O

We	O
then	O
blocked	O
CD11b	B-GP
/	O
CD18	B-GP
prior	O
to	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
.	O

CD11b	B-GP
inhibition	O
during	O
constitutive	O
spontaneous	O
neutrophil	O
PCD	O
decreased	O
cell	O
survival	O
by	O
20	O
%,	O
and	O
in	O
the	O
presence	O
of	O
S100A8	B-GP
/	O
9	O
,	O
CD11b	B-GP
inhibition	O
cut	O
the	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
50	O
−	O
75	O
%	O
(	O
Fig	O
.	O
5C	O
),	O
suggesting	O
that	O
S100A8	B-GP
/	O
9	O
may	O
exert	O
its	O
survival	O
effect	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
either	O
binding	O
or	O
expressing	O
CD11b	B-GP
,	O
a	O
known	O
receptor	O
involved	O
in	O
neutrophil	O
apoptosis	O
.	O

For	O
further	O
assessments	O
,	O
we	O
used	O
a	O
CHO	O
cell	O
line	O
transfected	O
with	O
CD11b	B-GP
/	O
CD18	B-GP
.	O

Transfected	O
CHO	O
cells	O
increased	O
binding	O
of	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
by	O
almost	O
twofold	O
in	O
comparison	O
with	O
control	O
CHO	O
cells	O
(	O
Fig	O
.	O
5C	O
,	O
upper	O
right	O
).	O

However	O
,	O
when	O
we	O
examined	O
the	O
effect	O
of	O
recombinant	O
S100A8	B-GP
/	O
9	O
on	O
CD11b	B-GP
/	O
CD18	B-GP
-	O
deficient	O
neutrophils	O
from	O
a	O
leukocyte	B-DS
adhesion	I-DS
deficiency	I-DS
(	O
LAD	B-DS
)	O
patient	O
,	O
results	O
were	O
less	O
clear	O
.	O

As	O
expected	O
,	O
CD11b	B-GP
-	O
deficient	O
neutrophils	O
showed	O
delayed	O
PCD	O
in	O
comparison	O
with	O
neutrophils	O
from	O
healthy	O
donors	O
(	O
Fig	O
.	O
5D	O
),	O
however	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
kept	O
its	O
protective	O
anti	O
-	O
apoptotic	O
effect	O
on	O
CD11b	B-GP
-	O
deficient	O
neutrophils	O
,	O
and	O
survival	O
was	O
increased	O
by	O
50	O
−	O
90	O
%.	O

This	O
supports	O
the	O
hypothesis	O
that	O
these	O
proteins	O
exert	O
their	O
survival	O
effect	O
only	O
partially	O
by	O
CD11b	B-GP
/	O
CD18	B-GP
,	O
and	O
other	O
receptors	O
are	O
involved	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
one	O
alternative	O
candidate	O
,	O
we	O
examined	O
a	O
G	B-GP
-	I-GP
coupled	I-GP
protein	I-GP
receptor	I-GP
.	O

Pertusis	B-GP
toxin	I-GP
,	O
which	O
abrogates	O
G	B-GP
-	I-GP
coupled	I-GP
protein	I-GP
receptor	I-GP
function	O
,	O
did	O
not	O
influence	O
the	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
(	O
Fig	O
.	O
5E	O
).	O

An	O
additional	O
possible	O
receptor	O
is	O
Toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
4	I-GP
[	O
29	O
].	O

Inhibiting	O
TLR4	B-GP
abrogated	O
the	O
survival	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
by	O
25	O
−	O
60	O
%	O
(	O
Fig	O
.	O
5F	O
),	O
suggesting	O
that	O
both	O
CD11b	B-GP
/	O
CD18	B-GP
and	O
TLR4	B-GP
may	O
be	O
involved	O
in	O
the	O
pathway	O
enabling	O
these	O
proteins	O
to	O
affect	O
neutrophil	O
PCD	O
.	O

Extracellular	B-GP
signal	I-GP
-	I-GP
regulated	I-GP
kinase	I-GP
(	O
ERK	B-GP
),	O
one	O
of	O
the	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinases	I-GP
(	O
MAPK	B-GP
),	O
is	O
involved	O
in	O
integrin	B-GP
signaling	O
and	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
in	O
general	O
.	O

It	O
appears	O
to	O
mediate	O
signals	O
promoting	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
,	O
as	O
reviewed	O
by	O
Roux	O
,	O
et	O
al	O
[	O
35	O
].	O

We	O
assessed	O
the	O
role	O
of	O
ERK	B-GP
in	O
the	O
neutrophil	O
S100A8	B-GP
/	O
9	O
survival	O
effect	O
using	O
intracellular	O
staining	O
of	O
phosphorylated	O
ERK	B-GP
.	O

Neutrophils	O
exposed	O
to	O
S100A8	B-GP
/	O
9	O
for	O
10	O
min	O
showed	O
more	O
than	O
a	O
threefold	O
increase	O
in	O
phosphorylation	O
of	O
the	O
ERK	B-GP
kinase	O
(	O
Fig	O
.	O
6A	O
).	O

This	O
activation	O
continues	O
to	O
a	O
lesser	O
extent	O
following	O
30	O
and	O
60	O
min	O
exposure	O
.	O

Furthermore	O
,	O
the	O
inhibitor	O
PD98059	O
(	O
MEK	B-GP
inhibitor	O
)	O
reduced	O
ERK	B-GP
phosphorylation	O
by	O
more	O
than	O
50	O
%	O
(	O
Fig	O
.	O
6B	O
)	O
and	O
abolished	O
the	O
S100A8	B-GP
/	O
9	O
survival	O
effect	O
by	O
50	O
−	O
100	O
%	O
at	O
various	O
concentrations	O
(	O
Fig	O
.	O
6C	O
),	O
suggesting	O
that	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
survival	O
effect	O
involves	O
the	O
MEK	B-GP
-	O
ERK	B-GP
signaling	O
pathway	O
.	O

Effects	O
of	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
are	O
mediated	O
through	O
the	O
MAPK	B-GP
-	O
ERK	B-GP
pathway	O
.	O

A	O
.	O
Phosphorylation	O
of	O
MAPK	B-GP
following	O
exposure	O
to	O
S100A8	B-GP
/	O
9	O
.	O

Freshly	O
isolated	O
neutrophils	O
with	O
or	O
without	O
treatment	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
for	O
various	O
times	O
as	O
indicated	O
,	O
and	O
then	O
prepared	O
for	O
intracellular	O
staining	O
with	O
mouse	B-OG
anti	O
-	O
human	B-OG
phospho	O
-	O
p44	B-GP
/	O
42	O
MAPK	B-GP
alexa	O
fluor	O
488	O
(	O
gray	O
)	O
or	O
isotype	O
control	O
(	O
black	O
),	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

In	O
the	O
presence	O
of	O
S100A8	B-GP
/	O
9	O
,	O
phosphorylation	O
was	O
increased	O
by	O
3	O
.	O
22	O
-	O
fold	O
after	O
10	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
1	O
.	O
5	O
-	O
fold	O
after	O
30	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
),	O
and	O
decayed	O
at	O
60	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Histograms	O
are	O
representative	O
of	O
3	O
independent	O
experiments	O
.	O
B	O
.	O
Reduced	O
phosphorylation	O
of	O
MAPK	B-GP
following	O
exposure	O
to	O
S100A8	B-GP
/	O
9	O
in	O
the	O
presence	O
of	O
PD98059	O
,	O
a	O
MAPK	B-GP
phosphorylation	O
inhibitor	O
.	O

Freshly	O
isolated	O
neutrophils	O
were	O
treated	O
with	O
the	O
inhibitor	O
PD98059	O
or	O
with	O
DMSO	O
as	O
a	O
control	O
for	O
30	O
min	O
,	O
and	O
then	O
treated	O
with	O
2	O
µg	O
/	O
ml	O
S100A8	B-GP
/	O
9	O
.	O

Cells	O
were	O
then	O
harvested	O
and	O
prepared	O
for	O
intracellular	O
staining	O
of	O
phospho	O
-	O
p44	B-GP
/	O
42	O
MAPK	B-GP
(	O
gray	O
)	O
or	O
isotype	O
control	O
(	O
black	O
),	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
.	O

Treatment	O
with	O
PD98059	O
inhibitor	O
reduced	O
phosphorylation	O
caused	O
by	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Histograms	O
are	O
representative	O
of	O
3	O
experiments	O
.	O
C	O
.	O
Effect	O
of	O
the	O
S100A8	B-GP
/	O
9	O
complex	O
in	O
the	O
presence	O
of	O
MAPK	B-GP
-	O
ERK	B-GP
inhibitor	O
.	O

The	O
effect	O
of	O
S100A8	B-GP
/	O
9	O
was	O
assessed	O
in	O
the	O
presence	O
of	O
PD98059	O
.	O

Freshly	O
isolated	O
neutrophils	O
were	O
treated	O
with	O
varying	O
combinations	O
and	O
concentrations	O
of	O
DMSO	O
(	O
white	O
bars	O
),	O
S100A8	B-GP
/	O
9	O
complex	O
(	O
gray	O
bars	O
),	O
or	O
S100A8	B-GP
/	O
9	O
complex	O
with	O
PD98059	O
(	O
black	O
bars	O
),	O
as	O
indicated	O
,	O
for	O
30	O
min	O
before	O
adding	O
S100A8	B-GP
/	O
9	O
.	O

Neutrophils	O
were	O
allowed	O
to	O
undergo	O
constitutive	O
spontaneous	O
PCD	O
.	O

Results	O
represent	O
the	O
percentage	O
of	O
viable	O
cells	O
according	O
to	O
Annexin	B-GP
V	I-GP
-	O
FITC	O
and	O
PI	O
staining	O
.	O

Data	O
is	O
representative	O
of	O
3	O
experiments	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O

Apoptotic	O
neutrophils	O
are	O
not	O
activated	O
neutrophils	O

As	O
S100A8	B-GP
/	O
9	O
was	O
mainly	O
reported	O
thus	O
far	O
to	O
be	O
released	O
during	O
inflammation	O
(	O
see	O
discussion	O
),	O
it	O
may	O
be	O
attributed	O
to	O
release	O
due	O
to	O
neutrophil	O
activation	O
.	O

We	O
wanted	O
to	O
further	O
verify	O
that	O
apoptotic	O
neutrophils	O
are	O
not	O
activated	O
due	O
to	O
extraction	O
method	O
or	O
in	O
vitro	O
effect	O
.	O

Therefore	O
we	O
analyzed	O
three	O
surface	O
molecules	O
that	O
are	O
upregulated	O
upon	O
neutrophil	O
activation	O
and	O
downregulated	O
upon	O
neutrophil	O
PCD	O
.	O

In	O
figures	O
S1	O
and	O
S2	O
,	O
CD16	B-GP
and	O
CD62L	B-GP
,	O
both	O
markers	O
of	O
neutrophil	O
activation	O
showed	O
clear	O
down	O
regulation	O
in	O
the	O
examined	O
neutrophils	O
,	O
in	O
correlation	O
to	O
apoptotic	O
state	O
[	O
36	O
].	O

In	O
addition	O
CD11b	B-GP
,	O
is	O
a	O
third	O
molecule	O
,	O
that	O
is	O
upregulated	O
upon	O
activation	O
was	O
downregulated	O
in	O
apoptotic	O
neutrophils	O
releasing	O
S100A8	B-GP
and	O
S100A9	B-GP
(	O
see	O
Figure	O
5	O
).	O

Taken	O
together	O
,	O
S100	B-GP
A8	I-GP
and	O
S100A9	B-GP
were	O
released	O
in	O
the	O
context	O
of	O
apoptotic	O
neutrophil	O
death	O
in	O
non	O
activated	O
neutrophils	O
.	O

Discussion	O

Neutrophils	O
are	O
responsible	O
for	O
the	O
body	O
'	O
s	O
rapid	O
and	O
effective	O
response	O
to	O
infection	B-DS
or	O
injury	O
[	O
37	O
].	O

Efficient	O
function	O
necessitates	O
an	O
optimal	O
balance	O
between	O
a	O
sufficient	O
number	O
of	O
blood	O
neutrophils	O
,	O
response	O
to	O
stimuli	O
,	O
and	O
transmigration	O
properties	O
,	O
on	O
one	O
hand	O
,	O
against	O
regulation	O
of	O
the	O
termination	O
of	O
a	O
neutrophil	O
-	O
mediated	O
inflammatory	O
response	O
on	O
the	O
other	O
.	O

Thus	O
,	O
control	O
of	O
neutrophil	O
turnover	O
in	O
the	O
bone	O
marrow	O
and	O
circulation	O
,	O
and	O
at	O
inflammatory	O
sites	O
,	O
is	O
key	O
to	O
both	O
homeostasis	O
and	O
inflammation	O
.	O

PCD	O
plays	O
a	O
critical	O
role	O
in	O
neutrophil	O
homeostasis	O
for	O
an	O
optimal	O
functioning	O
in	O
the	O
human	B-OG
body	O
.	O

Polymorphonuclears	O
comprise	O
approximately	O
75	O
%	O
of	O
all	O
nucleated	O
cells	O
in	O
the	O
hematopoietic	O
compartment	O
of	O
the	O
newborn	O
marrow	O
,	O
with	O
the	O
majority	O
being	O
neutrophils	O
.	O

Already	O
in	O
the	O
bone	O
marrow	O
,	O
large	O
-	O
scale	O
neutrophil	O
death	O
and	O
removal	O
of	O
neutrophils	O
by	O
phagocytes	O
are	O
seen	O
[	O
38	O
].	O
Yet	O
,	O
the	O
major	O
regulator	O
of	O
blood	O
neutrophil	O
counts	O
,	O
as	O
well	O
as	O
neutrophil	O
counts	O
at	O
inflammatory	O
sites	O
,	O
is	O
PCD	O
,	O
which	O
allows	O
only	O
a	O
short	O
life	O
span	O
,	O
with	O
modulation	O
according	O
to	O
needs	O
such	O
as	O
inflammation	O
.	O

Here	O
we	O
show	O
that	O
the	O
S100	B-GP
A8	I-GP
/	O
9	O
complex	O
regulates	O
neutrophil	O
number	O
and	O
PCD	O
in	O
response	O
to	O
neutrophil	O
concentration	O
,	O
by	O
an	O
anti	O
-	O
apoptotic	O
effect	O
.	O

S100A9	B-GP
(	O
MRP14	B-GP
)	O
and	O
S100A8	B-GP
(	O
MRP8	B-GP
)	O
constitute	O
roughly	O
40	O
%	O
of	O
the	O
cytosolic	O
protein	O
in	O
neutrophils	O
;	O
their	O
pure	O
abundance	O
implies	O
an	O
important	O
role	O
in	O
neutrophil	O
functions	O
.	O

However	O
,	O
our	O
understanding	O
of	O
the	O
mechanisms	O
implicating	O
both	O
molecules	O
in	O
neutrophil	O
/	O
monocyte	O
physiology	O
remains	O
incomplete	O
,	O
as	O
reviewed	O
by	O
Nacken	O
,	O
et	O
al	O
[	O
39	O
].	O

S100A9	B-GP
and	O
S100A8	B-GP
readily	O
form	O
hetero	O
-	O
and	O
homodimeric	O
,	O
trimeric	O
,	O
and	O
tetrameric	O
complexes	O
,	O
but	O
apparently	O
also	O
exert	O
specific	O
functions	O
as	O
monomers	O
.	O

It	O
has	O
been	O
suggested	O
that	O
S100A9	B-GP
plays	O
a	O
prominent	O
role	O
in	O
leukocyte	O
trafficking	O
and	O
arachidonic	O
acid	O
metabolism	O
,	O
and	O
elevated	O
S100A9	B-GP
and	O
S100A8	B-GP
levels	O
are	O
found	O
in	O
body	O
fluids	O
of	O
inflamed	O
tissues	O
.	O

When	O
neutrophils	O
undergo	O
PCD	O
,	O
they	O
release	O
S100A8	B-GP
/	O
9	O
,	O
which	O
partially	O
protects	O
surrounding	O
neutrophils	O
from	O
PCD	O
,	O
a	O
mechanism	O
that	O
may	O
be	O
of	O
crucial	O
importance	O
in	O
fine	O
-	O
tuning	O
neutrophil	O
concentrations	O
in	O
the	O
bone	O
marrow	O
and	O
blood	O
,	O
and	O
in	O
inflammatory	O
sites	O
.	O

This	O
finding	O
is	O
supported	O
by	O
the	O
decrease	O
in	O
bone	O
marrow	O
neutrophils	O
in	O
S100A9	B-GP
-	O
deficient	O
mice	B-OG
[	O
40	O
],	O
and	O
the	O
accumulation	O
of	O
S100A8	B-GP
/	O
9	O
at	O
inflammatory	O
sites	O
,	O
where	O
prolonged	O
survival	O
of	O
neutrophils	O
is	O
usually	O
needed	O
for	O
chemotaxis	O
and	O
neutrophil	O
adhesion	O
[	O
32	O
].	O

As	O
shown	O
in	O
figure	O
5A	O
and	O
supplemental	O
figures	O
1	O
and	O
2	O
,	O
apoptotic	O
neutrophils	O
were	O
not	O
activated	O
and	O
their	O
S100	B-GP
A8	I-GP
and	O
S100	O
A9	B-GP
release	O
was	O
associated	O
with	O
PCD	O
and	O
not	O
inflammation	O
or	O
activation	O
.	O

S100A8	B-GP
deficiency	O
is	O
lethal	O
[	O
41	O
],	O
thus	O
further	O
research	O
to	O
gain	O
understanding	O
of	O
the	O
role	O
of	O
S100A8	B-GP
/	O
9	O
is	O
partially	O
limited	O
to	O
animal	O
models	O
.	O

By	O
prolonging	O
neutrophil	O
life	O
,	O
S100A8	B-GP
/	O
9	O
accumulation	O
could	O
be	O
also	O
a	O
contributing	O
mechanism	O
to	O
autoimmune	O
conditions	O
and	O
the	O
development	O
of	O
chronic	O
inflammation	O
or	O
acute	O
sterile	O
danger	O
-	O
related	O
inflammation	O
.	O

In	O
conditions	O
such	O
as	O
gout	B-DS
,	O
monosodium	O
urate	O
monohydrate	O
crystals	O
induce	O
the	O
release	O
of	O
S100A8	B-GP
/	O
A9	B-GP
from	O
neutrophils	O
[	O
42	O
]	O
and	O
allow	O
inflammatory	O
attack	O
by	O
prolonging	O
neutrophil	O
life	O
.	O

High	O
S100A8	B-GP
/	O
9	O
levels	O
were	O
found	O
in	O
chronically	O
inflamed	O
joints	O
of	O
patients	O
with	O
rheumatoid	B-DS
arthritis	I-DS
[	O
43	O
].	O

Our	O
study	O
also	O
proposes	O
an	O
additional	O
possible	O
mechanism	O
for	O
neutropenia	B-DS
following	O
chemotherapy	O
,	O
suggesting	O
that	O
low	O
neutrophil	O
concentration	O
may	O
be	O
further	O
aggravated	O
due	O
to	O
accelerated	O
PCD	O
,	O
induced	O
at	O
low	O
neutrophil	O
concentrations	O
.	O

This	O
hypothesis	O
needs	O
further	O
investigation	O
.	O

We	O
were	O
also	O
able	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
enabling	O
S100A8	B-GP
/	O
9	O
function	O
.	O

S100A8	B-GP
/	O
9	O
clearly	O
upregulates	O
and	O
binds	O
to	O
CD11b	B-GP
,	O
previously	O
shown	O
to	O
be	O
a	O
major	O
regulator	O
of	O
neutrophil	O
PCD	O
[	O
44	O
],	O
with	O
possible	O
anti	O
-	O
or	O
pro	O
-	O
apoptotic	O
effect	O
.	O

However	O
,	O
as	O
shown	O
here	O
,	O
this	O
effect	O
was	O
retained	O
in	O
CD11b	B-GP
-	O
deficient	O
neutrophils	O
,	O
indicating	O
additional	O
mechanisms	O
such	O
as	O
TLR4	B-GP
.	O

Indeed	O
,	O
blocking	O
TLR4	B-GP
partially	O
abrogated	O
the	O
S100A8	B-GP
/	O
9	O
survival	O
effect	O
,	O
suggesting	O
that	O
S100A8	B-GP
/	O
9	O
is	O
an	O
endogenous	O
TLR4	B-GP
ligand	O
mediating	O
survival	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
TLR4	B-GP
agonist	O
LPS	O
and	O
others	O
inhibit	O
neutrophil	O
apoptosis	O
[	O
12	O
],	O
[	O
45	O
].	O

Here	O
we	O
show	O
for	O
the	O
first	O
time	O
an	O
endogenous	O
ligand	O
that	O
inhibits	O
neutrophil	O
apoptosis	O
.	O

Our	O
results	O
also	O
show	O
a	O
role	O
for	O
the	O
MEK	B-GP
/	O
ERK	B-GP
pathway	O
following	O
activation	O
by	O
S100A8	B-GP
/	O
9	O
.	O

This	O
pathway	O
has	O
been	O
well	O
documented	O
to	O
mediate	O
signaling	O
of	O
both	O
integrins	B-GP
and	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
,	O
supporting	O
a	O
role	O
for	O
CD11b	B-GP
,	O
TLR4	B-GP
,	O
and	O
possibly	O
additional	O
receptors	O
.	O

This	O
mechanism	O
has	O
been	O
shown	O
in	O
the	O
past	O
to	O
be	O
anti	O
-	O
apoptotic	O
in	O
neutrophils	O
via	O
both	O
intrinsic	O
[	O
46	O
]	O
and	O
extrinsic	O
[	O
47	O
]	O
PCD	O
pathways	O
.	O

The	O
correlation	O
between	O
beta2	B-GP
-	I-GP
integrin	I-GP
and	O
TLR4	B-GP
has	O
been	O
suggested	O
.	O

These	O
two	O
receptors	O
may	O
cooperate	O
to	O
produce	O
signals	O
that	O
are	O
transmitted	O
into	O
the	O
cell	O
.	O

Also	O
,	O
TLR4	B-GP
has	O
been	O
suggested	O
to	O
be	O
an	O
“	O
inside	O
-	O
out	O
”	O
regulator	O
of	O
the	O
beta2	B-GP
-	I-GP
integrins	I-GP
[	O
48	O
],	O
and	O
even	O
a	O
direct	O
TLR4	B-GP
-	O
beta2	B-GP
integrin	I-GP
interaction	O
has	O
been	O
suggested	O
[	O
49	O
].	O

Other	O
possible	O
functional	O
proteins	O
that	O
could	O
have	O
a	O
“	O
community	O
effect	O
”	O
may	O
be	O
found	O
in	O
the	O
secreted	O
proteome	O
of	O
apoptotic	O
cells	O
.	O

An	O
experimental	O
approach	O
using	O
2D	O
gel	O
may	O
discover	O
additional	O
candidate	O
proteins	O
and	O
functional	O
studies	O
may	O
establish	O
their	O
potential	O
role	O
in	O
PCD	O
.	O

In	O
summary	O
,	O
the	O
physiological	O
role	O
of	O
S100A8	B-GP
/	O
9	O
,	O
the	O
most	O
abundant	O
cytosol	O
protein	O
in	O
neutrophils	O
,	O
was	O
not	O
previously	O
understood	O
.	O

We	O
propose	O
that	O
at	O
physiological	O
protein	O
[	O
50	O
]	O
and	O
cell	O
concentrations	O
,	O
its	O
main	O
function	O
is	O
in	O
modulating	O
neutrophil	O
PCD	O
,	O
and	O
that	O
cell	O
concentration	O
is	O
regulated	O
by	O
an	O
autocrine	O
and	O
paracrine	O
mechanism	O
via	O
S100A8	B-GP
/	O
9	O
.	O

Finally	O
,	O
a	O
biological	O
“	O
proof	O
”	O
is	O
presented	O
here	O
,	O
suggesting	O
that	O
nature	O
encourages	O
“	O
community	O
life	O
”	O
at	O
the	O
level	O
of	O
neutrophil	O
survival	O
,	O
which	O
could	O
be	O
seen	O
as	O
a	O
cellular	O
illustration	O
for	O
human	B-OG
life	O
.	O

Supporting	O
Information	O

Apoptotic	O
neutrophils	O
downregulate	O
CD16	B-GP
.	O
The	O
expression	O
of	O
CD16	B-GP
(	O
Fc	B-GP
gamma	I-GP
RIII	I-GP
)	O
on	O
neutrophils	O
.	O

Freshly	O
isolated	O
neutrophils	O
CD16	B-GP
expession	O
at	O
time	O
0	O
(	O
black	O
line	O
,	O
median	O
fluorescence	O
of	O
382	O
)	O
and	O
following	O
12	O
h	O
of	O
spontaneous	O
PCD	O
(	O
gray	O
line	O
,	O
median	O
fluorescence	O
of	O
35	O
).	O

Isotype	O
control	O
is	O
shown	O
as	O
filled	O
histogram	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Apoptotic	O
neutrophils	O
downregulate	O
CD62L	B-GP
.	O
The	O
expression	O
of	O
CD62L	B-GP
(	O
L	B-GP
-	I-GP
selectin	I-GP
)	O
on	O
neutrophils	O
.	O

Freshly	O
isolated	O
neutrophils	O
CD62L	B-GP
expession	O
at	O
time	O
0	O
(	O
black	O
line	O
,	O
median	O
fluorescence	O
of	O
791	O
)	O
and	O
following	O
12	O
h	O
of	O
spontaneous	O
PCD	O
(	O
gray	O
line	O
,	O
median	O
fluorescence	O
of	O
27	O
).	O

Isotype	O
control	O
is	O
shown	O
as	O
filled	O
histogram	O
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Apoptosis	O
-	O
related	O
proteins	O
during	O
spontaneous	O
constitutive	O
PCD	O
in	O
the	O
presence	O
of	O
S100A8	B-GP
/	O
9	O
.	O
SDS	O
-	O
PAGE	O
of	O
McL1	B-GP
,	O
Bcl	B-GP
-	I-GP
xl	I-GP
,	O
A1	B-GP
,	O
Bcl2	B-GP
,	O
and	O
survivin	B-GP
in	O
spontaneous	O
constitutive	O
apoptosis	O
,	O
with	O
and	O
without	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
.	O

McL1	B-GP
(	O
39	O
KD	O
)	O
and	O
Bcl	B-GP
-	I-GP
xl	I-GP
(	O
26	O
KD	O
)	O
were	O
detected	O
in	O
all	O
conditions	O
.	O

A1	B-GP
(	O
20KD	O
)	O
was	O
detected	O
from	O
freshly	O
isolated	O
neutrophils	O
but	O
expression	O
was	O
downregulated	O
significantly	O
by	O
spontaneous	O
constitutive	O
apoptosis	O
.	O

Addition	O
of	O
S100A8	B-GP
/	O
9	O
did	O
not	O
rescue	O
protein	O
expression	O
.	O

Bcl2	B-GP
(	O
25KD	O
)	O
and	O
survivin	B-GP
(	O
19KD	O
)	O
were	O
not	O
detected	O
under	O
any	O
experimental	O
conditions	O
.	O

The	O
lysates	O
of	O
40	O
×	O
106	O
neutrophils	O
under	O
different	O
conditions	O
,	O
including	O
freshly	O
isolated	O
,	O
after	O
8	O
–	O
10	O
h	O
of	O
spontaneous	O
constitutive	O
PCD	O
,	O
or	O
after	O
8	O
–	O
10	O
h	O
of	O
spontaneous	O
constitutive	O
PCD	O
with	O
addition	O
of	O
S100A8	B-GP
/	O
9	O
,	O
were	O
loaded	O
and	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
as	O
described	O
in	O
Experimental	O
Procedures	O
.	O

Proteins	O
were	O
transferred	O
to	O
the	O
PVDF	O
membrane	O
and	O
exposed	O
to	O
the	O
appropriate	O
primary	O
antibody	B-GP
according	O
to	O
manufacturers	O
'	O
instructions	O
,	O
and	O
then	O
to	O
secondary	O
antibody	B-GP
conjugated	O
with	O
HRP	B-GP
.	O

(	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Additional	O
details	O
of	O
methods	O
used	O
in	O
proteomics	O
and	O
programmed	O
cell	O
death	O
evaluation	O
.	O

(	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

